Valrubicin is a semisynthetic anthracycline antineoplastic agent primarily used for the intravesical treatment of invasive bladder cancer that is refractory to other therapies. By inhibiting DNA synthesis… Read more
Valrubicin is a semisynthetic anthracycline antineoplastic agent primarily used for the intravesical treatment of invasive bladder cancer that is refractory to other therapies. By inhibiting DNA synthesis and topoisomerase II activity, this drug effectively targets malignant cells. This category provides essential reference standards for valrubicin, including the active pharmaceutical ingredient, the pharmacopeial impurity dianhydrovalrubicin, and specialized resolution mixtures containing related substances. These high-quality materials are critical for laboratories conducting impurity profiling, method validation, and stability testing. Researchers and quality control professionals rely on these reference standards to accurately identify degradation products, monitor purity levels, and ensure compliance with regulatory pharmacopeial requirements during the development and manufacturing of this oncology medication. Utilizing these comprehensive analytical tools facilitates precise quantification and verification of valrubicin drug substance throughout the pharmaceutical lifecycle.